ANDA 202600, held by Eugia Pharma. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 202600 (Ondansetron Hydrochloride Preservative Free), held by Eugia Pharma, was first approved by FDA on Dec 21, 2012, with 6 approved supplements and 0 published complete response letters.
Ondansetron Injection is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. postoperative nausea and/or vomiting. 1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 21, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron Hydrochloride Preservative FreeEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Sep 26, 2023 | Supplement 13Manufacturing · Standard review | Approved | None posted |
| Mar 1, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Aug 19, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Aug 19, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 9, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 9, 2015 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 21, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters